Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population

被引：0
|
作者：
Michelino De Laurentiis
Simona Borstnar
Mario Campone
Ellen Warner
Javier Salvador Bofill
William Jacot
Susan Dent
Miguel Martin
Alistair Ring
Paul Cottu
Janice Lu
Eva Ciruelos
Hamdy A. Azim
Sanjoy Chatterjee
Katie Zhou
Jiwen Wu
Lakshmi Menon-Singh
Claudio Zamagni
机构：
[1] Istituto Nazionale Tumori IRCCS “Fondazione Pascale”,Division of Breast Medical Oncology, Department of Breast and Thoracic Oncology Director
[2] Institute of Oncology Ljubljana,Gregorio Marañón General University Hospital, GEICAM
[3] Western Cancer Institute,University Hospital 12 de Octubre
[4] Sunnybrook Health Sciences Centre,Faculty of Medicine
[5] Virgen del Rocío University Hospital,Duke Cancer Institute
[6] Biomedicine Institute,undefined
[7] Montpellier Cancer Institute,undefined
[8] The Ottawa Hospital Cancer Centre,undefined
[9] Universidad Complutense,undefined
[10] CIBERONC,undefined
[11] Royal Marsden Hospital NHS Foundation Trust,undefined
[12] Curie Institute,undefined
[13] USC Norris Comprehensive Cancer Center,undefined
[14] Clara Campal Comprehensive Cancer Center (HM CIOCC),undefined
[15] Cairo University,undefined
[16] Tata Medical Center,undefined
[17] Novartis Pharmaceuticals Corporation,undefined
[18] Azienda Ospedaliero-Universitaria Di Bologna,undefined
[19] Duke University School of Medicine,undefined
来源：
Breast Cancer Research and Treatment | 2022年 / 191卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：223 / 224
页数：1
相关论文
共 50 条
  • [41] Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC
    Chu, Tianqing
    Zhong, Runbo
    Zhong, Hua
    Zhang, Bo
    Zhang, Wei
    Shi, Chunlei
    Qian, Jialin
    Zhang, Yanwei
    Chang, Qing
    Zhang, Xueyan
    Dong, Yu
    Teng, Jiajun
    Gao, Zhiqiang
    Qiang, Huiping
    Nie, Wei
    Zhao, Yiming
    Han, Yuchen
    Chen, Ya
    Han, Baohui
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : 643 - 652
  • [42] A phase I study of sunitinib plus paclitaxel for first-line treatment of advanced breast cancer: preliminary results.
    Kozloff, M. F.
    Chuang, E.
    Roy, J.
    Starr, A.
    Gowland, P. A.
    Tarpey, M. J.
    Coliler, M.
    Verk, L.
    Kern, K.
    Miller, K.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S273 - S273
  • [43] A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer
    Steven J. Cohen
    Mark M. Zalupski
    Manuel R. Modiano
    Paul Conkling
    Yehuda Z. Patt
    Peg Davis
    Robert T. Dorr
    Michelle L. Boytim
    Evan M. Hersh
    Cancer Chemotherapy and Pharmacology, 2010, 66 : 287 - 294
  • [44] A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer
    Cohen, Steven J.
    Zalupski, Mark M.
    Modiano, Manuel R.
    Conkling, Paul
    Patt, Yehuda Z.
    Davis, Peg
    Dorr, Robert T.
    Boytim, Michelle L.
    Hersh, Evan M.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (02) : 287 - 294
  • [45] Ribociclib plus letrozole in subgroups of special clinical interest with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Subgroup analysis of the phase IIIb CompLEEment-1 trial
    Cottu, Paul
    Ring, Alistair
    Abdel-Razeq, Hikmat
    Marchetti, Paolo
    Cardoso, Fatima
    Bofill, Javier Salvador
    Martin, Miguel
    Menon-Singh, Lakshmi
    Wu, Jiwen
    De Laurentiis, Michelino
    BREAST, 2022, 62 : 75 - 83
  • [46] Trastuzumab plus capecitabine and docetaxel as first-line therapy for metastatic breast cancer: Phase II results
    Gennatas, C. G.
    Michalaki, V.
    Gennatas, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [47] Overall survival subgroup analysis by metastatic site from the phase 3 MONALEESA-2 study of first-line ribociclib plus letrozole in postmenopausal patients with advanced HR+/HER2-breast cancer
    O'Shaughnessy, Joyce
    Stemmer, Salomon M.
    Burris, Howard A.
    Yap, Yoon-Sim
    Sonke, Gabe
    Hart, Lowell
    Campone, Mario
    Petrakova, Katarina
    Winer, Eric P.
    Janni, Wolfgang
    Conte, Pierfranco
    Cameron, David A.
    Andre, Fabrice
    Arteaga, Carlos
    Zarate, Juan Pablo
    Chakravartty, Arunava
    Taran, Tetiana
    Le Gac, Fabienne
    Serra, Paolo
    Hortobagyi, Gabriel N.
    CANCER RESEARCH, 2022, 82 (04)
  • [48] Results of a phase II study of pemetrexed as first-line chemotherapy for advanced or metastatic breast cancer
    Robert, N. J.
    Conkling, P. R.
    Kuefler, P. R.
    McIntyre, K. J.
    Zhan, F.
    Asmar, L.
    Wang, Y.
    Shonukan, O. O.
    O'Shaughnessy, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [49] Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: Analysis of survival and update of efficacy from the international letrozole breast cancer group - Reply
    Mouridsen, H
    Chaudri-Ross, HA
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (15) : 3200 - 3201
  • [50] First-line ribociclib plus letrozole in postmenopausal women with HR+, HER2-advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial
    Janni, Wolfgang
    Alba, Emilio
    Bachelot, Thomas
    Diab, Sami
    Gil-Gil, Miguel
    Beck, Thaddeus J.
    Ryvo, Larisa
    Lopez, Rafael
    Tsai, Michaela
    Esteva, Francisco J.
    Zamora Aunon, Pilar
    Kral, Zdenek
    Ward, Patrick
    Richards, Paul
    Pluard, Timothy J.
    Sutradhar, Santosh
    Miller, Michelle
    Campone, Mario
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 169 (03) : 469 - 479
12345